Last reviewed · How we verify

NCT06202209

The Impact of Autonomic Function on Atrial Fibrillation Recurrence After Pulmonary Vein Ablation

Status unknown Last updated 11 January 2024
What this trial tests

trial testing Circumferential Pulmonary Vein Isolation in Atrial Fibrillation Recurrent in 100 participants. Status unknown.

Timeline
13 September 2023
Primary endpoint
30 June 2024
30 October 2024

Quick facts

Lead sponsorChina National Center for Cardiovascular Diseases
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date13 September 2023
Primary completion30 June 2024
Estimated completion30 October 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

Adults 18 to 75, any sex, with Atrial Fibrillation Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective and observational study. The investigator speculated that the use of DC in patients with paroxysmal AF can serve as a predictor for early and late AF recurrence following CPVI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation Recurrent

Currently open trials in the same condition.

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06202209.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing